The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Hundreds of millions of people around the world live with major depressive disorder (MDD), making it ... communities about the difference between esketamine versus ketamine, and whether esketamine ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...